11/06/2026
Unregulated GLP-1 products made the news last Saturday.
But this is not only a story about unsafe products. It is also a story about access, safety and proper medical care.
The HPRA has reported a sharp rise in detained GLP-1 type products, from 1,582 in 2024 to 48,752 in 2025.
These are prescription medicines. They should be prescribed, supplied and monitored through regulated healthcare pathways.
People do not usually seek unsafe alternatives because they are reckless. Often, they are trying to access treatment for a chronic disease in a system where regulated options can feel limited.
spoke to the Irish Independent about what this can mean clinically and why proper monitoring matters.
People living with obesity deserve safe, regulated, evidence-based care.
Well done to Sean Po***ck for the carefully researched piece.